Navy@3x

Oxular

David Fellows Chair

About Us, Board / By

David is the CEO of AGTC and Chair of the Oxular Board. He has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson …

David Fellows Chair Read More »

OXU-005 mob

HPR mob, Pipeline / By

OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …

OXU-005 mob Read More »

OXU-001 mob (DME)

HPR mob, Pipeline / By

OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …

OXU-001 mob (DME) Read More »

OXU-003

Ocular oncology, Pipeline / By

OXU-003 is a potential first-in-class registered treatment for retinoblastoma. OXU-003 is an innovative stable, sustained-release preparation of a proprietary chemotherapy agent. It is designed to be safely delivered in the suprachoroidal space, adjacent to primary retinoblastoma tumors using Oxulumis microcatheter. Once delivered, OXU-003 is designed to release the anti-cancer drug over prescribed treatment cycles. The …

OXU-003 Read More »

OXU-001 (DME)

High prevalence retina, Pipeline / By

OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …

OXU-001 (DME) Read More »

OXU-005

High prevalence retina, Pipeline / By

OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …

OXU-005 Read More »

Oxular in Drug Discovery World

Latest-3, news / By

An excellent summary about the potential of our lead program, OXU-001, from Drug Discovery World.   “An innovative sustained release formulation of dexamethasone currently under investigation for use in DME offers the potential for effective anti-inflammatory treatment with significantly fewer injections and a high likelihood of fewer side effects, as its levels in the vitreous …

Oxular in Drug Discovery World Read More »

Scroll to Top